Therapy  ||| S:0 E:8 ||| NN
with  ||| S:8 E:13 ||| IN
high-doses  ||| S:13 E:24 ||| JJ
of  ||| S:24 E:27 ||| IN
antithrombin  ||| S:27 E:40 ||| JJ
III  ||| S:40 E:44 ||| NNP
in  ||| S:44 E:47 ||| IN
patients  ||| S:47 E:56 ||| NNS
with  ||| S:56 E:61 ||| IN
septic  ||| S:61 E:68 ||| JJ
shock  ||| S:68 E:74 ||| NN
and  ||| S:74 E:78 ||| CC
agranulocytosis  ||| S:78 E:94 ||| VBG
The  ||| S:94 E:98 ||| DT
aim  ||| S:98 E:102 ||| NN
of  ||| S:102 E:105 ||| IN
the  ||| S:105 E:109 ||| DT
study  ||| S:109 E:115 ||| NN
was  ||| S:115 E:119 ||| VBD
to  ||| S:119 E:122 ||| TO
assess  ||| S:122 E:129 ||| VB
efficacy  ||| S:129 E:138 ||| VBN
of  ||| S:138 E:141 ||| IN
high-doses  ||| S:141 E:152 ||| JJ
ofantithrombin  ||| S:152 E:167 ||| NN
111  ||| S:167 E:171 ||| CD
( ||| S:171 E:172 ||| -LRB-
AT ||| S:172 E:174 ||| NNP
)  ||| S:174 E:176 ||| -RRB-
for  ||| S:176 E:180 ||| IN
treatment  ||| S:180 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
septic  ||| S:193 E:200 ||| JJ
shock  ||| S:200 E:206 ||| NN
in  ||| S:206 E:209 ||| IN
patients  ||| S:209 E:218 ||| NNS
with  ||| S:218 E:223 ||| IN
an  ||| S:223 E:226 ||| DT
agranulocytosis ||| S:226 E:241 ||| NN
.  ||| S:241 E:243 ||| .
Prospective ||| S:243 E:254 ||| JJ
,  ||| S:254 E:256 ||| ,
controlled  ||| S:256 E:267 ||| VBD
study.  ||| S:267 E:274 ||| CD
29  ||| S:274 E:277 ||| CD
patients  ||| S:277 E:286 ||| NNS
from  ||| S:286 E:291 ||| IN
18  ||| S:291 E:294 ||| CD
to  ||| S:294 E:297 ||| TO
74  ||| S:297 E:300 ||| CD
years  ||| S:300 E:306 ||| NNS
old ||| S:306 E:309 ||| JJ
,  ||| S:309 E:311 ||| ,
with  ||| S:311 E:316 ||| IN
blood  ||| S:316 E:322 ||| NN
diseases  ||| S:322 E:331 ||| NNS
complicated  ||| S:331 E:343 ||| VBN
with  ||| S:343 E:348 ||| IN
septic  ||| S:348 E:355 ||| JJ
shock  ||| S:355 E:361 ||| NN
Dates  ||| S:361 E:367 ||| NNS
of  ||| S:367 E:370 ||| IN
study ||| S:370 E:375 ||| NN
:  ||| S:375 E:377 ||| :
from  ||| S:377 E:382 ||| IN
2006  ||| S:382 E:387 ||| CD
to  ||| S:387 E:390 ||| TO
2012 ||| S:390 E:394 ||| CD
.  ||| S:394 E:396 ||| .
The  ||| S:396 E:400 ||| DT
patients  ||| S:400 E:409 ||| NNS
were  ||| S:409 E:414 ||| VBD
randomized  ||| S:414 E:425 ||| VBN
into  ||| S:425 E:430 ||| IN
two  ||| S:430 E:434 ||| CD
groups ||| S:434 E:440 ||| NNS
.  ||| S:440 E:442 ||| .
Group-1  ||| S:442 E:450 ||| NNP
included  ||| S:450 E:459 ||| VBD
14  ||| S:459 E:462 ||| CD
patients ||| S:462 E:470 ||| NNS
,  ||| S:470 E:472 ||| ,
who  ||| S:472 E:476 ||| WP
did  ||| S:476 E:480 ||| VBD
not  ||| S:480 E:484 ||| RB
receive  ||| S:484 E:492 ||| VB
AT  ||| S:492 E:495 ||| NNP
and  ||| S:495 E:499 ||| CC
group-2  ||| S:499 E:507 ||| NNP
included  ||| S:507 E:516 ||| VBD
15  ||| S:516 E:519 ||| CD
patients  ||| S:519 E:528 ||| NNS
who  ||| S:528 E:532 ||| WP
received  ||| S:532 E:541 ||| VBD
AT ||| S:541 E:543 ||| NNP
.  ||| S:543 E:545 ||| .
Demographic  ||| S:545 E:557 ||| JJ
indicators ||| S:557 E:567 ||| NNS
,  ||| S:567 E:569 ||| ,
condition  ||| S:569 E:579 ||| NN
severity  ||| S:579 E:588 ||| NN
according  ||| S:588 E:598 ||| VBG
to  ||| S:598 E:601 ||| TO
APACHE  ||| S:601 E:608 ||| NNP
II ||| S:608 E:610 ||| NNP
,  ||| S:610 E:612 ||| ,
level  ||| S:612 E:618 ||| NN
of  ||| S:618 E:621 ||| IN
thrombocytopenia ||| S:621 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
levels  ||| S:639 E:646 ||| NNS
ofplasma  ||| S:646 E:655 ||| JJ
procalcitonin ||| S:655 E:668 ||| NN
,  ||| S:668 E:670 ||| ,
interleukin-6  ||| S:670 E:684 ||| NNP
( ||| S:684 E:685 ||| -LRB-
IL-6 ||| S:685 E:689 ||| NNP
)  ||| S:689 E:691 ||| -RRB-
and  ||| S:691 E:695 ||| CC
C-reactive  ||| S:695 E:706 ||| JJ
protein  ||| S:706 E:714 ||| NN
( ||| S:714 E:715 ||| -LRB-
CRP ||| S:715 E:718 ||| NNP
)  ||| S:718 E:720 ||| -RRB-
were  ||| S:720 E:725 ||| VBD
the  ||| S:725 E:729 ||| DT
same  ||| S:729 E:734 ||| JJ
in  ||| S:734 E:737 ||| IN
both  ||| S:737 E:742 ||| DT
groups ||| S:742 E:748 ||| NNS
.  ||| S:748 E:750 ||| .
Level  ||| S:750 E:756 ||| NN
of  ||| S:756 E:759 ||| IN
AT  ||| S:759 E:762 ||| NNP
was  ||| S:762 E:766 ||| VBD
decreased  ||| S:766 E:776 ||| VBN
in  ||| S:776 E:779 ||| IN
both  ||| S:779 E:784 ||| DT
groups ||| S:784 E:790 ||| NNS
;  ||| S:790 E:792 ||| :
however  ||| S:792 E:800 ||| RB
it  ||| S:800 E:803 ||| PRP
was  ||| S:803 E:807 ||| VBD
higher  ||| S:807 E:814 ||| JJR
in  ||| S:814 E:817 ||| IN
the  ||| S:817 E:821 ||| DT
group-1  ||| S:821 E:829 ||| NNP
( ||| S:829 E:830 ||| -LRB-
50 ||| S:830 E:832 ||| CD
%  ||| S:832 E:834 ||| NN
vs.  ||| S:834 E:838 ||| IN
60 ||| S:838 E:840 ||| CD
% ||| S:840 E:841 ||| NN
,  ||| S:841 E:843 ||| ,
p  ||| S:843 E:845 ||| CD
< ||| S:845 E:847 ||| SYM
0.05 ||| S:847 E:851 ||| CD
) ||| S:851 E:852 ||| -RRB-
.  ||| S:852 E:854 ||| .
In  ||| S:854 E:857 ||| IN
the  ||| S:857 E:861 ||| DT
group-1 ||| S:861 E:868 ||| NNP
,  ||| S:868 E:870 ||| ,
microorganisms  ||| S:870 E:885 ||| NN
were  ||| S:885 E:890 ||| VBD
found  ||| S:890 E:896 ||| VBN
in  ||| S:896 E:899 ||| IN
the  ||| S:899 E:903 ||| DT
blood  ||| S:903 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
9  ||| S:912 E:914 ||| CD
patients ||| S:914 E:922 ||| NNS
.  ||| S:922 E:924 ||| .
In  ||| S:924 E:927 ||| IN
the  ||| S:927 E:931 ||| DT
group-2 ||| S:931 E:938 ||| NNP
,  ||| S:938 E:940 ||| ,
the  ||| S:940 E:944 ||| DT
microorganisms  ||| S:944 E:959 ||| NN
were  ||| S:959 E:964 ||| VBD
found  ||| S:964 E:970 ||| VBN
in  ||| S:970 E:973 ||| IN
the  ||| S:973 E:977 ||| DT
blood  ||| S:977 E:983 ||| NN
of  ||| S:983 E:986 ||| IN
11  ||| S:986 E:989 ||| CD
patients ||| S:989 E:997 ||| NNS
.  ||| S:997 E:999 ||| .
Inflammation  ||| S:999 E:1012 ||| JJ
markers  ||| S:1012 E:1020 ||| NN
were  ||| S:1020 E:1025 ||| VBD
decreased  ||| S:1025 E:1035 ||| VBN
after  ||| S:1035 E:1041 ||| IN
the  ||| S:1041 E:1045 ||| DT
treatment  ||| S:1045 E:1055 ||| NN
of  ||| S:1055 E:1058 ||| IN
septic  ||| S:1058 E:1065 ||| JJ
shock  ||| S:1065 E:1071 ||| NN
in  ||| S:1071 E:1074 ||| IN
both  ||| S:1074 E:1079 ||| DT
groups  ||| S:1079 E:1086 ||| NNS
( ||| S:1086 E:1087 ||| -LRB-
p  ||| S:1087 E:1088 ||| CD
< ||| S:1088 E:1089 ||| SYM
0.05 ||| S:1089 E:1093 ||| CD
) ||| S:1093 E:1094 ||| -RRB-
.  ||| S:1094 E:1096 ||| .
The  ||| S:1096 E:1100 ||| DT
decreasing  ||| S:1100 E:1111 ||| NN
of  ||| S:1111 E:1114 ||| IN
procalcitonin  ||| S:1114 E:1128 ||| NN
in  ||| S:1128 E:1131 ||| IN
group-1  ||| S:1131 E:1139 ||| NNP
was  ||| S:1139 E:1143 ||| VBD
from  ||| S:1143 E:1148 ||| IN
43.8  ||| S:1148 E:1153 ||| CD
to  ||| S:1153 E:1156 ||| TO
1  ||| S:1156 E:1158 ||| CD
ng ||| S:1158 E:1160 ||| CD
/ ||| S:1160 E:1161 ||| CD
ml  ||| S:1161 E:1164 ||| NN
in  ||| S:1164 E:1167 ||| IN
14  ||| S:1167 E:1170 ||| CD
days  ||| S:1170 E:1175 ||| NNS
and  ||| S:1175 E:1179 ||| CC
from  ||| S:1179 E:1184 ||| IN
12.8  ||| S:1184 E:1189 ||| CD
to  ||| S:1189 E:1192 ||| TO
1.6  ||| S:1192 E:1196 ||| CD
ng ||| S:1196 E:1198 ||| CD
/ ||| S:1198 E:1199 ||| CD
ml  ||| S:1199 E:1202 ||| NN
in  ||| S:1202 E:1205 ||| IN
7  ||| S:1205 E:1207 ||| CD
days  ||| S:1207 E:1212 ||| NNS
in  ||| S:1212 E:1215 ||| IN
group-2 ||| S:1215 E:1222 ||| CD
.  ||| S:1222 E:1224 ||| .
The  ||| S:1224 E:1228 ||| DT
decreasing  ||| S:1228 E:1239 ||| NN
of  ||| S:1239 E:1242 ||| IN
CRP  ||| S:1242 E:1246 ||| NNP
in  ||| S:1246 E:1249 ||| IN
group-1  ||| S:1249 E:1257 ||| NNP
was  ||| S:1257 E:1261 ||| VBD
from  ||| S:1261 E:1266 ||| IN
224  ||| S:1266 E:1270 ||| CD
to  ||| S:1270 E:1273 ||| TO
114  ||| S:1273 E:1277 ||| CD
mg ||| S:1277 E:1279 ||| CD
/ ||| S:1279 E:1280 ||| CD
l  ||| S:1280 E:1282 ||| NN
in  ||| S:1282 E:1285 ||| IN
7  ||| S:1285 E:1287 ||| CD
days  ||| S:1287 E:1292 ||| NNS
and  ||| S:1292 E:1296 ||| CC
from  ||| S:1296 E:1301 ||| IN
146  ||| S:1301 E:1305 ||| CD
to  ||| S:1305 E:1308 ||| TO
60  ||| S:1308 E:1311 ||| CD
mg ||| S:1311 E:1313 ||| CD
/ ||| S:1313 E:1314 ||| CD
l  ||| S:1314 E:1316 ||| NN
in  ||| S:1316 E:1319 ||| IN
14  ||| S:1319 E:1322 ||| CD
days  ||| S:1322 E:1327 ||| NNS
in  ||| S:1327 E:1330 ||| IN
group-2 ||| S:1330 E:1337 ||| CD
.  ||| S:1337 E:1339 ||| .
The  ||| S:1339 E:1343 ||| DT
decreasing  ||| S:1343 E:1354 ||| NN
of  ||| S:1354 E:1357 ||| IN
IL-6  ||| S:1357 E:1362 ||| CD
in  ||| S:1362 E:1365 ||| IN
group-1  ||| S:1365 E:1373 ||| NNP
was  ||| S:1373 E:1377 ||| VBD
from  ||| S:1377 E:1382 ||| IN
1617  ||| S:1382 E:1387 ||| CD
to  ||| S:1387 E:1390 ||| TO
100  ||| S:1390 E:1394 ||| CD
pg ||| S:1394 E:1396 ||| CD
/ ||| S:1396 E:1397 ||| CD
ml  ||| S:1397 E:1400 ||| NN
in  ||| S:1400 E:1403 ||| IN
3  ||| S:1403 E:1405 ||| CD
days  ||| S:1405 E:1410 ||| NNS
and  ||| S:1410 E:1414 ||| CC
from  ||| S:1414 E:1419 ||| IN
5895  ||| S:1419 E:1424 ||| CD
to  ||| S:1424 E:1427 ||| TO
77  ||| S:1427 E:1430 ||| CD
pg ||| S:1430 E:1432 ||| CD
/ ||| S:1432 E:1433 ||| CD
ml  ||| S:1433 E:1436 ||| NN
in  ||| S:1436 E:1439 ||| IN
7  ||| S:1439 E:1441 ||| CD
days  ||| S:1441 E:1446 ||| NNS
in  ||| S:1446 E:1449 ||| IN
group-2 ||| S:1449 E:1456 ||| CD
.  ||| S:1456 E:1458 ||| .
A  ||| S:1458 E:1460 ||| DT
level  ||| S:1460 E:1466 ||| NN
of  ||| S:1466 E:1469 ||| IN
AT  ||| S:1469 E:1472 ||| NNP
was  ||| S:1472 E:1476 ||| VBD
increased  ||| S:1476 E:1486 ||| VBN
only  ||| S:1486 E:1491 ||| RB
in  ||| S:1491 E:1494 ||| IN
group-2  ||| S:1494 E:1502 ||| NNP
( ||| S:1502 E:1503 ||| -LRB-
under  ||| S:1503 E:1509 ||| IN
12 ||| S:1509 E:1511 ||| CD
%  ||| S:1511 E:1513 ||| NN
per  ||| S:1513 E:1517 ||| IN
day ||| S:1517 E:1520 ||| NN
) ||| S:1520 E:1521 ||| -RRB-
.  ||| S:1521 E:1523 ||| .
28-day  ||| S:1523 E:1530 ||| CD
survival  ||| S:1530 E:1539 ||| NN
was  ||| S:1539 E:1543 ||| VBD
higher  ||| S:1543 E:1550 ||| JJR
in  ||| S:1550 E:1553 ||| IN
group-2  ||| S:1553 E:1561 ||| NNP
( ||| S:1561 E:1562 ||| -LRB-
60  ||| S:1562 E:1565 ||| CD
+ ||| S:1565 E:1566 ||| CD
/ ||| S:1566 E:1567 ||| CD
-  ||| S:1567 E:1569 ||| :
13 ||| S:1569 E:1571 ||| CD
%  ||| S:1571 E:1573 ||| NN
vs.  ||| S:1573 E:1577 ||| IN
45  ||| S:1577 E:1580 ||| CD
+ ||| S:1580 E:1581 ||| CD
/ ||| S:1581 E:1582 ||| CD
-  ||| S:1582 E:1584 ||| :
13 ||| S:1584 E:1586 ||| CD
% ||| S:1586 E:1587 ||| NN
,  ||| S:1587 E:1589 ||| ,
p  ||| S:1589 E:1590 ||| CD
< ||| S:1590 E:1591 ||| SYM
0.05 ||| S:1591 E:1595 ||| CD
) ||| S:1595 E:1596 ||| -RRB-
.  ||| S:1596 E:1598 ||| .
We  ||| S:1598 E:1601 ||| PRP
did  ||| S:1601 E:1605 ||| VBD
not  ||| S:1605 E:1609 ||| RB
find  ||| S:1609 E:1614 ||| VB
any  ||| S:1614 E:1618 ||| DT
complications  ||| S:1618 E:1632 ||| NNS
of  ||| S:1632 E:1635 ||| IN
the  ||| S:1635 E:1639 ||| DT
treatment  ||| S:1639 E:1649 ||| NN
with  ||| S:1649 E:1654 ||| IN
AT  ||| S:1654 E:1657 ||| NNP
concentrate ||| S:1657 E:1668 ||| NN
.  ||| S:1668 E:1670 ||| .
Treatment  ||| S:1670 E:1680 ||| NN
of  ||| S:1680 E:1683 ||| IN
septic  ||| S:1683 E:1690 ||| JJ
shock  ||| S:1690 E:1696 ||| NN
with  ||| S:1696 E:1701 ||| IN
high-doses  ||| S:1701 E:1712 ||| JJ
of  ||| S:1712 E:1715 ||| IN
antithrombin  ||| S:1715 E:1728 ||| JJ
III  ||| S:1728 E:1732 ||| NNP
was  ||| S:1732 E:1736 ||| VBD
effective  ||| S:1736 E:1746 ||| JJ
and  ||| S:1746 E:1750 ||| CC
safe  ||| S:1750 E:1755 ||| JJ
in  ||| S:1755 E:1758 ||| IN
patients  ||| S:1758 E:1767 ||| NNS
with  ||| S:1767 E:1772 ||| IN
an  ||| S:1772 E:1775 ||| DT
agranulocytosis ||| S:1775 E:1790 ||| NN
.  ||| S:1790 E:1792 ||| .
